Insider Trading & Ownership of Clay B. Siegall

Location
Bothell, WA
Summary
The estimated net worth of Clay B. Siegall is at least $166,224,999 dollars as of 31 Mar 2026. Clay B. Siegall is the President & CEO, Director of Seagen Inc. and owns shares of Seagen Inc. stock worth about $152.53M. Clay B. Siegall is the President and CEO, Director of Immunome Inc. and owns shares of Immunome Inc. (IMNM) stock worth about $13.59M. Clay B. Siegall is the Director of Shattuck Labs, Inc. and owns shares of Shattuck Labs, Inc. (STTK) stock worth about $111.1K.
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Clay B. Siegall and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Quick Takeaways

  • Clay B. Siegall has 5 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $166,224,999.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Seagen Inc. ($152,527,740).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Clay B. Siegall

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
SGEN Seagen Inc. President & CEO, Director $152,527,740 12 May 2022
IMNM Immunome Inc. President and CEO, Director $13,586,147 +$1,749,660 +15% 27 Mar 2026
STTK Shattuck Labs, Inc. Director $111,112 25 Aug 2025
NRIX Nurix Therapeutics, Inc. Director 05 May 2022
TRML Tourmaline Bio, Inc. Director 28 Oct 2025

Insider Transactions Reported by Clay B. Siegall:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .